We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+13.58%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$17B
AUM Growth
+$1.79B
Cap. Flow
-$229M
Cap. Flow %
-1.35%
Top 10 Hldgs %
33.75%
Holding
1,490
New
144
Increased
706
Reduced
317
Closed
73

Top Buys

Rank Stock Value
1
O icon
Realty Income
O
+$448M
2
AMT icon
American Tower
AMT
+$132M
3
HIW icon
Highwoods Properties
HIW
+$92.2M
4
WELL icon
Welltower
WELL
+$79.2M
5
PLD icon
Prologis
PLD
+$71.1M

Top Sells

Rank Stock Value
1
VER
VEREIT, Inc.
VER
+$434M
2
CONE
CyrusOne Inc Common Stock
CONE
+$386M
3
WY icon
Weyerhaeuser
WY
+$118M
4
HR icon
Healthcare Realty
HR
+$68.6M
5
VTR icon
Ventas
VTR
+$64.7M

Sector Composition

Rank Sector Weight
1 Real Estate 60.4%
2 Technology 9.49%
3 Consumer Discretionary 4.17%
4 Communication Services 4.01%
5 Financials 3.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMO
1201
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4K ﹤0.01%
498
– –
SNDX icon
1202
Syndax Pharmaceuticals
SNDX
$1.69B
$4K ﹤0.01%
167
– –
XENE icon
1203
Xenon Pharmaceuticals
XENE
$6.21B
$4K ﹤0.01%
141
– –
RVNC
1204
DELISTED
Revance Therapeutics, Inc.
RVNC
$4K ﹤0.01%
246
– –
ACRS icon
1205
Aclaris Therapeutics
ACRS
$723M
$3K ﹤0.01%
+179
New +$2.71K
AKRO
1206
DELISTED
Akero Therapeutics
AKRO
$3K ﹤0.01%
119
– –
ALXO icon
1207
ALX Oncology
ALXO
$258M
$3K ﹤0.01%
138
– –
BVS icon
1208
Bioventus
BVS
$899M
$3K ﹤0.01%
+173
New +$2.46K
CRBU icon
1209
Caribou Biosciences
CRBU
$145M
$3K ﹤0.01%
+176
New +$3.42K
DAWN
1210
DELISTED
Day One Biopharmaceuticals
DAWN
$3K ﹤0.01%
+181
New +$3.72K
DSGN icon
1211
Design Therapeutics
DSGN
$741M
$3K ﹤0.01%
+162
New +$2.78K
GLUE icon
1212
Monte Rosa Therapeutics
GLUE
$1.83B
$3K ﹤0.01%
+136
New +$2.85K
GOSS icon
1213
Gossamer Bio
GOSS
$92.3M
$3K ﹤0.01%
260
– –
IDYA icon
1214
IDEAYA Biosciences
IDYA
$3.44B
$3K ﹤0.01%
132
– –
IGMS
1215
DELISTED
IGM Biosciences
IGMS
$3K ﹤0.01%
88
– –
IMVT icon
1216
Immunovant
IMVT
$7.9B
$3K ﹤0.01%
394
– –
INVA icon
1217
Innoviva
INVA
$1.6B
$3K ﹤0.01%
191
– –
IPSC icon
1218
Century Therapeutics
IPSC
$364M
$3K ﹤0.01%
+159
New +$2.99K
KURA icon
1219
Kura Oncology
KURA
$794M
$3K ﹤0.01%
227
– –
MCRB icon
1220
Seres Therapeutics
MCRB
$46M
$3K ﹤0.01%
16
– –
MGNX icon
1221
MacroGenics
MGNX
$233M
$3K ﹤0.01%
209
– –
MGTX icon
1222
MeiraGTx Holdings
MGTX
$1.06B
$3K ﹤0.01%
130
+48
+59% +$919
MXCT icon
1223
MaxCyte
MXCT
$108M
$3K ﹤0.01%
+293
New +$3.15K
PGEN icon
1224
Precigen
PGEN
$1.94B
$3K ﹤0.01%
708
– –
PMVP icon
1225
PMV Pharmaceuticals
PMVP
$57.6M
$3K ﹤0.01%
+132
New +$3.19K
47 48
49
50 51

Similar funds

SAM
Storebrand Asset Management Lysaker, Norway $34.8B AUM 25.49% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
VIA
Vanguard Investments Australia Victoria, Australia $34.6B AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Daiwa Securities Group's Q4 2021 Portfolio in Review

As of Q4 2021, Daiwa Securities Group held 1,490 positions worth $17B, up 12% from $15.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Daiwa Securities Group's Q4 2021 filing shows 144 new, 706 increased, 317 reduced and 73 closed positions. Its largest new stake was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M. The largest sale was VEREIT, Inc., an estimated $434M.

By sector, the portfolio is most concentrated in Real Estate at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Daiwa Securities Group's largest Q4 2021 buy was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M.
  • Daiwa Securities Group added most to Realty Income in Q4 2021, an estimated $448M increase.
  • Daiwa Securities Group's biggest Q4 2021 reduction was CyrusOne Inc Common Stock, cutting an estimated $386M.
  • Daiwa Securities Group fully exited VEREIT, Inc. in Q4 2021, selling an estimated $434M.
  • Daiwa Securities Group's ten largest holdings make up 34% of its $17B portfolio in Q4 2021.
  • Daiwa Securities Group opened 144 new positions and closed 73 in Q4 2021.
  • Daiwa Securities Group's portfolio value rose 12% quarter-over-quarter to $17B.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.